The RESHAW clinical trial evaluated the company’s Veri-te resveratrol in 125 postmenopausal women and the results were published in a peer-reviewed journal
Rontgen picture of male pelvis.
Swiss biotech company Evolva has unveiled positive results from the resveratrol supporting healthy ageing in women (RESHAW), a clinical study on the bone mineral density of postmenopausal women.
The RESHAW clinical trial evaluated the company’s Veri-te resveratrol in 125 postmenopausal women and the results were published in a peer-reviewed journal.
The clinical trial was conducted in Australia by the researchers from the University of Newcastle’s Clinical Nutrition Research Centre, including Rachel Wong, Jay Jay Thaung Zaw, Professor Cory J Xian and Emeritus Professor Peter Howe.
Peter Howe said: “Participants with greater bone resorption at baseline showed a greater reduction of plasma C-terminal telopeptide type-1 collagen with resveratrol, suggesting a greater potential for resveratrol to improve bone formation in those individuals at risk of rapid bone loss.
“The increase in bone mineral density in the femoral neck resulted in an improvement in T-Score and a reduction in the 10-year probability of major and hip fracture risk.
“It is important to note that these benefits were observed in postmenopausal women without osteoporosis, and a sub-analysis suggests that resveratrol could be used synergistically with calcium plus Vitamin D supplements to further reduce the risk of total and hip fractures.”
RESHAW trial is evaluating the impact of resveratrol on body composition
The company said that RESHAW trial is a large-scale clinical study of resveratrol, supported by the National Health and Medical Research Council and the Australian Research Council (NHMRC-ARC).
In addition, the clinical study trial is aimed at investigating the impact of resveratrol supplementation on body composition, including bone mineral density in critical regions, and measuring biomarkers of bone metabolism.
In the study, participants were randomised to take two capsules containing 75mg of Evolva’s Veri-te resveratrol ingredient daily or a matching placebo supplement for 12 months, followed by the alternate treatment for a further 12-month period.
The study demonstrated that Evolva’s Veri-te resveratrol improved bone density in the lumbar spine and femoral neck of postmenopausal women, with a 7.2% relative reduction of plasma C-terminal telopeptide type-1 collagen, which is a marker of bone resorption.
Evolva health ingredients VP Clare Panchoo said: “These first two peer-reviewed publications from the RESHAW clinical study provide the evidence that supplementation with Veri-te resveratrol should be a key strategy for the design of effective supplements that may lessen the decline in both brain and bone health as women age.
“The RESHAW reporting continues to point to the ability of resveratrol to improve the microcirculation and deliver blood to tissues, thereby supporting brain health and helping Veri-te resveratrol offers customers a guarantee of quality together with strong scientific backing and versatility in application, which can both inspire and enable customers to develop innovative and award-winning products.”
Evolva is engaged in the research, development and commercialisation of products based on nature, including flavours and fragrances, health ingredients and health protection.